Related Experiment Video
Updated: May 22, 2026
10:35
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
A comparison between intravenous and subcutmaneous immunogobulin.
Mary E Braine1, Amanda Woodall
1School of Nursing, Midwifery and Social Work, College of Health and Social Care, University of Salford,
British Journal of Nursing (Mark Allen Publishing)
|May 29, 2012
Summary
Subcutaneous immunoglobulin (SCIg) therapy offers a potentially better treatment experience for multifocal motor neuropathy (MMN) patients compared to intravenous immunoglobulin (IVIg). This approach may improve quality of life and treatment satisfaction for individuals with MMN.
Area of Science:
- Neurology
- Immunology
Background:
- Multifocal motor neuropathy (MMN) is a rare immune-mediated disorder causing progressive motor weakness.
- Current treatment relies on high-dose intravenous immunoglobulin (IVIg), which can be burdensome for patients.
- Subcutaneous immunoglobulin (SCIg) is an emerging alternative for MMN management.
Purpose of the Study:
- To explore patient experiences with SCIg for MMN.
- To compare quality of life and treatment satisfaction between SCIg and IVIg.
- To identify potential benefits of SCIg for MMN management.
Main Methods:
- Mixed-methods study design.
- Patient-reported outcomes assessment.
- Qualitative and quantitative data analysis.
Main Results:
- Patients receiving SCIg reported a more desirable treatment experience.
- SCIg may lead to improved quality of life and treatment satisfaction in a subset of MMN patients.
- Home-based SCIg administration offers potential advantages.
Conclusions:
- Home SCIg therapy presents a promising alternative to IVIg for multifocal motor neuropathy.
- Patient-centered approaches are crucial in managing rare neurological disorders.
- Further research should explore long-term efficacy and patient preferences for SCIg in MMN.
Related Concept Videos
01:25Routes of Drug Administration: Parenteral
The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
01:29Drug Delivery: Parenteral Route
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
01:17Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...